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Dendritic cell-speciﬁc intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN) is an important pattern recognition
receptor on dendritic cells (DCs), and its expression shows signiﬁcant cytological and histological speciﬁcity, being interleukine-4
(IL-4) dependent. The signaling pathways through which IL-4 regulates expression of DC-SIGN are still unclear. We used phorbol
12-myristate 13-acetate- (PMA-) diﬀerentiated THP-1 cells as the in vitro model of monocyte/macrophage cells to study the
signaling pathways involved in IL-4-regulated expression of DC-SIGN. We found that a high expression of DC-SIGN could be
induced by IL-4 at the levels of mRNA and cell surface protein. Upregulated expression of DC-SIGN was almost completely
blocked by the speciﬁc inhibitor of ERK pathway, and partly reduced by the speciﬁc inhibitors of JAK-STAT and NF-κBp a t h w a y s .
The activation of the three signaling pathways was directly conﬁrmed by testing the phosphorylation of protein kinase within the
cytoplasm and nucleus over time. The analysis of cis-acting elements of DC-SIGN promoter showed that the activity of DC-SIGN
promoter without Ets-1 transcription factors binding site almost completely disappeared. Our results demonstrated that multiple
signaling pathways are involved in IL-4 induced high expression of DC-SIGN on THP-1 cells, in which ERK pathway is the main
signaling pathway and mediated by the Ets-1 transcription factors binding site.
1.Introduction
Dendritic cell-speciﬁc intercellular adhesion molecule
(ICAM)-3-grabbing nonintegrin (DC-SIGN; also called
CD209) is a type II transmembrane protein with a C-type
lectin extracellular domain [1, 2]. Functionally, DC-SIGN
mediates antigen capture for processing and presentation
in the context of major histocompatibility complex class II
molecules [3, 4]. DC-SIGN plays an important role in estab-
lishing the initial contact between dendritic cells (DCs) and
restingTlymphocytesthroughitsrecognitionofICAM-3[2]
and also mediates DCs traﬃcking through interactions with
endothelialICAM-2[5].Inaddition,asapatternrecognition
receptor (PRR), DC-SIGN function is subverted by numer-
ous pathogens as a strategy to escape from immunosurveil-
lance [6, 7]. In the case of human immunodeﬁciency virus
(HIV),DC-SIGNbindsgp120withhighaﬃnity[1],captures
HIV in the periphery, and promotes eﬃcient infection of
cells expressing HIV receptors and coreceptors [8, 9]. DC-
SIGN also mediates virus uptake by dendritic cells through
endocytosis, where HIV remains infectious for prolonged
periods of time, evades immune surveillance, and is efﬁ-
ciently transferred to CD4+ T cells in lymph nodes, like a
“Trojan horse” [8]. Therefore, DC-SIGN plays a key role in
HIVtransmission, especiallyintermsof sexualtransmission.
Expression of DC-SIGN is restricted to speciﬁc cells and
tissues. DC-SIGN is preferentially expressed on immature
D C si np e r i p h e r a lt i s s u e sa n din-vitro-derived monocyte-
derived dendritic cells (MDDCs) [2, 5] and is usually con-
sidered as a DC-speciﬁc phenotypic marker. It has also been
detected on synovial, placenta, and alveolar macrophages,
and on a small subset of CD14+ peripheral blood DCs
[10–12]. Trumpfheller et al. [13] analyzed the function of
DC-SIGN in diﬀerent cells, including monocyte-derived2 Journal of Biomedicine and Biotechnology
DCs, and three diﬀerent DC-SIGN-expressing transfectants
termed THP-1, 293, and HOS. They found that the function
of DC-SIGN in HIV-1 transmission depends on its cellular
context, since only DCs and the THP monocyte cell line, but
not 293 and HOS, are able to use DC-SIGN to retain HIV-
1 in a highly infectious state for several days. The existing
studies indicate that the expression and function of DC-
SIGNispreciselyregulated.However,lessisknownaboutthe
mechanism of the regulated expression of DC-SIGN. Relloso
etal.[14] foundthat the expression of DC-SIGN on MDDCs
was induced by interleukine-4 (IL-4) through the JAK-STAT
signaling pathway. However, the ERK signaling pathway is
also considered to be a candidate pathway for DC-SIGN
expression since it is involved in most IL-4/IL-4 receptor
eﬀects [15, 16]. Given the important role of the functional
activities displayed by DC-SIGN, it is necessary to determine
the signaling pathways and factors controlling its expression.
Since the low level of DCs in human peripheral blood,
immature MDDC in vitro studies is mostly derived from
peripheral blood monocytes in the presence of GM-CSF
and IL-4 [17, 18]. The expression of DC-SIGN is largely
d e p e n d e n to nI L - 4[ 14], a cytokine whose action drives
monocyte/macrophages into the “alternative activation”
pathway [19]. THP-1 cells, which are widely used as a mono-
cyte/macrophage diﬀerentiation model [20, 21], can be in-
ducedtoexpressfunctionalDC-SIGNwhendiﬀerentiatedby
protein kinase C (PKC) activators and IL-4 [22]. It has been
reportedthatthesignalingmechanismsregulatingDC-SIGN
expression in monocyte-derived macrophages and DCs also
controltheexpressionofthispathogenreceptorindiﬀerenti-
atedTHP-1cells,implyingthattheTHP-1celllinerepresents
a useful cellular system for the analysis of the regulated
expression and functional activities of DC-SIGN [14]. Here,
we used THP-1 cells as the in vitro model of MDDCs to
study the signaling pathways of IL-4-induced expression of
DC-SIGN. We found that multiple signaling pathways were
involved in the process of IL-4-regulated DC-SIGN expres-
sion, the major of which was the ERK signaling pathway.
2.MaterialsandMethods
2.1. Cytokines and Antibodies. Recombined human IL-4 was
obtained from R&D System (Minneapolis, USA) and used
at 1000units/mL. PMA was obtained from Sigma (St. Louis,
USA) and used at 10ng/mL. The NF-κB inhibitor Helenalin,
JAK2/3inhibitorAG490,p38MAPKinhibitorSB202190,and
the MEK1/2 inhibitor PD98059 were purchased from Merck
(Gibbstown,USA)andusedat1μM(Hellenalin),300μg/mL
(AG490), 5μM (SB202190), and 50μM (PD98059). Mouse
anti-human DC-SIGN monoclonal antibody was obtained
from R&D System.
2.2. Cell Culture. The acute monocytic leukemia cell line
THP-1 was derived from the American Type Culture Col-
lection (ATCC, Rockville, USA) and cultured in RPMI
1640 medium supplemented with 10% fetal bovine serum
(completemedium),beingmaintainedat3–5×105 cells/mL.
THP-1 cells were routinely seeded at 5 × 105 cells/mL in
tissue culture dishes, and diﬀerentiation was induced by
treatment with PMA (10ng/mL) either alone or in com-
bination with IL-4 (1000units/mL). IL-4 was added into
the cells after treatment with PMA for 18h with complete
medium and starvation for 6h with RPMI 1640 medium
supplemented with PMA (10ng/mL). Fetal bovine serum
was added to 10% 2h after IL-4 addition and diﬀerentiation
was allowed to proceed for 72h. For inhibition of signaling
pathways, inhibitors of the signaling pathways were added
30minbeforeIL-4additionandtheprocessofdiﬀerentiation
was as per the above description. For subsequent analysis,
diﬀerentiated THP-1 cells were detached from tissue culture
plates by incubation in PBS 10mM EDTA on ice.
2.3. RNA Extraction and Real-Time Quantitative PCR. Total
RNA from untreated or diﬀerentiated by PMA, PMA, plus
IL-4,orsignaling-inhibitor-treatedTHP-1cellswasextracted
using total RNA extraction kit (Invitrogen) and reverse
transcribed into cDNA in a total volume of 20μL. Real-time
polymerase chain reaction (PCR) of DC-SIGN mRNA was
performed by amplifying samples of target cDNA in a DNA
Engine Chromo 4 real-time quantitative PCR system (Bio-
Rad, Hercules, USA) using an SYBR Green kit (Roche Diag-
nostics GmbH). Oligonucleotides were used for DC-SIGN
mRNA ampliﬁcation (CD209 sense: 5 -GGGAATTCA-
GAGTGGGGTGACATGAGTGAC-3  and CD209 antisense:
5 -CCCCAAGCTTGTGAAGTTCTGCTACGCAGGAG-3 )
and the inner conference β-actin mRNA ampliﬁcation (β-
actinsense:5 -GGGAATTCAGAGTGGGGTGACATGAGT-
GAC-3  and β-actin antisense: 5 -CCCCAAGCTTGTGAA-
GTTCTGCTACGCAGGAG-3 ). The reaction system was
am i x t u r eo f1 0 μL SYBR Green Master Mix (Qiagen),
0.2μLo fe a c ho l i g o n u c l e o t i d e sp r i m e r s ,2 μL cDNA, and
the ﬁnal volume was taken to 20μL with water. Real-time
PCR was performed for 40 cycles of denaturation (95◦C,
45s), annealing (62◦C, 30s), and extension (72◦C, 30s), and
double-strandedDNAwasmeasuredat86◦Caftereachcycle.
Each sample was tested three times.
2.4. Flow Cytometry and Antibodies. Expression of DC-SIGN
on surface of untreated or diﬀerentiated by PMA, PMA+IL-
4, or signaling-inhibitor-treated THP-1 cells was determined
by ﬂow cytometry. The harvested THP-1 cells were washed
twice with PBS, incubated with 10μL mouse anti-human
DC-SIGN monoclonal antibody (25–50μg/mL) for 1h, and
washed again. Secondary antibody was added and incubated
for 1h. Flow cytometry analysis was performed with a four-
color FACScan ﬂow cytometer (Becton Dickinson). Results
are expressed as the expression index: percentage of marker-
positive cells and the MFI.
2.5. Detection of Signaling Kinases and Factors in Cytoplasm
and Nucleus of THP-1 Cells. THP-1 cells diﬀerentiated with
PMA for 18h were starved for 6h with RPMI 1640 medium
supplemented with PMA (10ng/mL) and then induced with
IL-4 (1000units/mL). Cells were put on ice and washed by
ice cooled PBS to stop the phosphorylation of the kinases
and factors of signaling pathways 0min, 5min, 10min,Journal of Biomedicine and Biotechnology 3
Table 1: The sequence of the primers for DC-SIGN, the promoters, and internal reference.
Sequence of the primers
P1 (the forward primer of DC-SIGN promoter) 5 -ATCATACGCGTATGAGTCCTTCTCCCTGTC-3 
P2 (the reverse primer of DC-SIGN promoter) 5 -TGTAAGATCTGTCACCCCACTCTCCCCCAG-3 
P3 (5  side primer of AP-1 site) 5 -CAAAAGACTAGTGGAAAGCATCAGA-3 
P4 (3  side primer of AP-1 site) 5 -CCCTACCCAACTTCCTGTTTCTCTT-3 
P5 (joint primer beside AP-1 site) 5 -CCACTAGTCTTTTGCCCTACCCAACTT-3 
P6 (5 side primer of Ets-1 site) 5 -TGGGTAGGGATCTGTCATCCA-3 
P7 (3  side primer of Ets-1 site) 5 -TCTCTTTCTGTGGGAGACTAGAT-3 
P8 (joint primer beside Ets-1 site) 5 -CCACAGAAAGAGATGGGTAGGGATCT-3 
P9 (the forward primer of DC-SIGN) 5 -AGAGTGGGGTGACATGAGTGAC-3 
P10 (the reverse primer of DC-SIGN) 5 -GTGAAGTTCTGCTACGCAGGAG-3 
P11 (the forward primer of β-Actin) 5 -CTCCATCCTGGCCTCGCTGT-3 
P12 (the reverse primer of β-Actin) 5 -GCTGTCACCTTCACCGTTCC-3 
ACGCGT:t h er e s t r i c t i o ns i t e so fM L uI ;A G A T C T : the restriction sites of Bgl II.
20min, 30min, and 60min after the addition of IL-4.
Cytoplasmic protein and nuclear protein were extracted
using cytoplasmic/nuclear protein extraction kit (PIERCE).
Phosphorylated and nonphosphorylated signaling kinas-
es and factors were determined by Western Blot as described
before [23]. 10μg of each sample was subjected to SDS-
PAGE under reducing conditions and transferred onto an
immobilon polyvinylidene diﬂuoride membrane (Millipore,
Bedford, USA). After blocking with 5% nonfat dry milk
in 50mM Tris-HCl, pH 7.6, 150mM NaCl, 0.1% Tween 20,
1-2μg/mL primary antibodies were added and incubated
overnight at 4◦C. After incubation with HRP labeled
secondary antibodies for 2h, the membrane was exposed
with the VersaDoc 5000MP Image Analysis System (Bio-
Rad). Detection of signaling kinases and factors was carried
out using speciﬁc monoclonal antibodies anti-STAT6,
anti-ERK1/2, anti-NF-κBp65, anti-IκB, and anti-p38.
And phosphorylated kinases and factors were detected
using anti-phospho-STAT6-Tyr641, anti-phospho-ERK1/2-
Thr202/Tyr204, anti-phospho-NF-κBp65-Ser536, anti-
phospho-IκB-Thr19/Ser23, and anti-phospho-p38 MAPK-
Thr180/Tyr182 (Cell Signaling Technology, Beverly, USA).
β-actin and tubullin were detected as the inner reference
using the polyclonal antibodies.
2.6. Construction of DC-SIGN Promoter Luciferase Reporter
PlasmidsandtheActivityDetection. Total DNA was extracted
from THP-1 cells and the whole region of DC-SIGN
promoter was ampliﬁed by PRC using the forward and
reverse primers of P1 and P2, where underlined residues
represent additional sequences containing MLu I or Bgl
II restriction sites, as shown in Table 1. The fragments of
DC-SIGN promoter on both sides of AP-1 were ampliﬁed
using the forward and reverse primers of P1 and P3, and
P2 and P4 separately, and then were linked by PRC with
a combing primer P5, and forward and reverse primers of
P1 and P2, conforming the DC-SIGN promoter without
AP-1 binding site. And the DC-SIGN promoter without
Ets-1 binding site was ampliﬁed in the same way, using
primers of P1, P2, P6, P7, and P8, as shown in Table 1.T h e
mixture of PCR reaction consisted of 0.2μL DNA template,
2μL forward/reverse primers (10mM), 4μLM g C l 2(25mM),
4μL dNTP (2.5mM), 5μL1 0 ×PCR buﬀer, 0.5μL Pfu DNA
polymerase (2U/μL, promega), and the ﬁnal volume was
takento50μLwithwater.PCRwasperformedfor30cyclesof
denaturation (95◦C, 30s), annealing (57–62◦C, 1min), and
extension (72◦C, 1min). The fragments were identiﬁed by
gene sequencing (Invitrogen). The fragments of DC-SIGN
promoters were double digested with MLu I and Bgl II and
gel puriﬁed and ligated into MLu I- and Bgl II-digested pGL-
3/Basic and pGL-3/Enhancer luciferase reporter vectors to
generate complete DC-SIGN promoter luciferase reporter
plasmids and those without AP-1 and Ets-1bingding sites.
Transfection of DC-SIGN promoter luciferase reporter plas-
mids and the inner control pRL-TK in Hacat and 293T
cells (ATCC) was accomplished using Trans Fast (Promega).
DC-SIGN promoter luciferase reporter plasmids and the
inner control pRL-TK were electransfected into THP-1 cells
using Amaxa cell line transfection kit (Amaxa, Germany)
in Amaxa Nucleofector electroporation apparatus (Amaxa,
Germany) with the V-010 electroporation procedure. Each
sample was repeated six times. The transfected cells were
cultured for 48h, and the luciferase activities of DC-SIGN
promoter luciferase reporter plasmids and the inner control
pRL-TK were detected using the dual luciferase reporter
assay kit (Promega) in GloMax96 microplate luminometer
(Promega). The relative activity of DC-SIGN promoter
was expressed by the ratio of activity between DC-SIGN
promoter luciferase reporter plasmids and the inner control
pRL-TK.
2.7. Statistics. Every test was repeated three times and data
was shown as mean±SE. The statistical signiﬁcance (P val-
ues)oftheresultswascalculatedbyusing SPSSv.13software.
Student’s t-test was used to compare between two groups4 Journal of Biomedicine and Biotechnology
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Figure 1: IL-4-induced high expression of DC-SIGN on THP-1 cells over time. THP-1 cells were treated with or without PMA for 24 hours,
or with PMA for 24 hours and IL-4 for up to 72 hours. (a), the quantitative analysis of the level of DC-SIGN mRNA in diﬀerentiated THP-1
cells by PMA and IL-4 by SYBR Green real-time PCR. (b), analysis of induced DC-SIGN expression on surface of diﬀerentiated THP-1
cells by ﬂow cytometry. The percentage of positive cells (top number) and mean ﬂuorescence intensity (ﬁgure below) are shown. ∗means
P<0.05; ∗∗means P<0.01.
whileone-wayANOVAwasusedwhencomparingmorethan
three groups.
3. Results
3.1. IL-4 Induced High Expression of DC-SIGN on THP-1
Cells. We determined the DC-SIGN mRNA and expression
on untreated, PMA-treated, and PMA plus IL-4-treated
THP-1 cells at diﬀerent times of diﬀerentiation. The results
of mRNA testing by real-time quantitative PCR showed that
PMA diﬀerentiation for 24 hours increased the level of DC-
SIGN mRNA in THP-1 cells up to 30 folds and induction
of IL-4 greatly enhanced the level of DC-SIGN mRNA. The
highestlevelofDC-SIGNmRNAwasdetectedwheninduced
by PMA and IL-4 for 24 hours, which was 469 ± 148 times
higher than that of untreated THP-1 cells (P<0.01, see
Figure 1(a)).
DC-SIGN is a transmembrane protein. Therefore, we
further detected DC-SIGN expression on cell surface by ﬂow
cytometry. The results showed that PMA induced a low
level of DC-SIGN expression on THP-1 cell surface with the
percentage of 14.54 ± 3.97% DC-SIGN+ THP-1 cells and
the mean ﬂuorescence intensity (MFI) of 18.12 ± 7.51. IL-4
greatly enhanced the percentage of DC-SIGN+ THP-1 cells,
and the MFI at the same time. The highest expression of
DC-SIGN on THP-1 cells diﬀerentiated by PMA plus IL-4,Journal of Biomedicine and Biotechnology 5
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Figure 2: Inhibition of DC-SIGN expression by speciﬁc inhibitors of signaling pathways. DC-SIGN expression was detected on THP-1 cells
diﬀerentiated by PMA, PMA plus IL-4, or PMA plus IL-4 treated with speciﬁc inhibitors (Helenalin, AG490, SB202190, and PD98059). (a),
The relative levels of DC-SIGN mRNA detected by real-time PCR. The levels of DC-SIGN mRNA in PMA plus IL-4 treated THP-1 cells were
valued as 100%, and used as a reference. ∗means P<0.05; ∗∗means P<0.01. (b), DC-SIGN expression on surface of THP-1 cells detected
by ﬂow cytometry. The percentage of positive cells (top number) and mean ﬂuorescence intensity (number below) are shown.
with the percentage of 61.23 ± 15.21% DC-SIGN+ THP-1
cells and the MFI of 56.80 ± 21.35, was found at 72 hours
(24h for PMA and 48h for PMA plus IL-4). We found
that the majority of the cells were overactivated and aging
after diﬀerentiated by PMA plus IL-4 for 96 hours, and
the proportion of dead cells increased. Although the DC-
SIGN (+) THP-1 ratio was declined, the MFI remained high
(Figure 1(b)).
3.2. Intracellular Signaling Pathways Involved in DC-SIGN
Expression. The stimulation by IL-4 on IL-4 receptor was
mainly transducted through the JAK-STAT and ERK signal
pathways [24–27]. In addition, our previous study suggested
that the NF-κB signaling pathway may also be involved in the
expressionofDC-SIGN[28].Weselectedfourdiﬀerentalter-
native pathways (ERK, NF-κB, JAK-STAT, and p38MAPK)
as the target signaling pathways, and detected the DC-SIGN
expressionbyblockingthecorrespondingsignalingpathways
with speciﬁc inhibitors.
Real-time PCR showed that inhibitor of ERK pathway
(PD98059) blocked the expression of DC-SIGN mRNA by
83.84 ± 4.13%, which was the most obvious among the four
inhibitors, followed by the inhibitor of JAK-STAT pathway
(AG490) which decreased DC-SIGN mRNA by 67.16 ±
5.67%. Blocking of the NF-κB pathway also decreased DC-
SIGN mRNA by 40.08 ± 10.12%. Blocking of DC-SIGN
mRNA by inhibitor p38MAPK pathway (SB202190) was not
signiﬁcant (see Figure 2(a)).
We further detected expression of DC-SIGN on THP-
1 cell membrane using ﬂow cytometry by blocking the sig-
naling pathways with speciﬁc inhibitors. DC-SIGN expres-
sion was decreased from DC-SIGN+ rate of 54.03 ± 7.66%6 Journal of Biomedicine and Biotechnology
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Figure 3: Phosphorylation of kinase and factors over time in the signaling pathways within 120min in IL-4-induced THP-1 cells. (a), the
cytoplasmic levels of protein kinase and phosphorylated kinase in the signaling pathways. (b), the concentration of phosphorylated protein
kinase in the nucleus over time. Protein kinase with “p” means phosphorylated protein kinase.
(MFI = 60.53±15.42)onTHP-1cellsinducedbyPMA+IL-4
to16.42±5.88%(MFI = 29.26±9.76)ondiﬀerentiatedTHP-
1 cells treated by PD98059, close to the PMA-treated THP-1
cells (15.17 ± 4.47%, MFI = 18.12 ± 7.58.), which mean the
nearly total block of IL-4 induction. AG490 decreased DC-
SIGN expression by 55.8% with DC-SIGN+ THP-1 cells of
23.89 ± 5.12% (MFI = 39.67 ± 15.46). Hellenalin decreased
DC-SIGN expression by 40% with DC-SIGN+ THP-1 cells
of 32.69 ± 6.69% (MFI = 53.27 ± 18.53). Expression of DC-
SIGN on THP-1 cells treated with SB202190 was almost not
reduced (see Figure 2(b)).
3.3. Phosphorylation of Kinase and Factors over Time in
the Signaling Pathways. In order to get the direct evidence
of activation of the signaling pathways, we examined the
phosphorylation of kinase and factors in the signaling
pathways. The result of Western Blot test showed that, within
the 120min after addition of IL-4, the cytoplasmic levels
of phosphorylated ERK1/2 of ERK pathway, phosphorylated
STAT6ofJAK-STATpathway,andphosphorylatedNF-κBp65
and I-κBo fN F - κB pathway increased over time from a
low concentration to a high concentration, which indicated
directly the activation of the three signaling pathways.
However, the level of phosphorylated p38 of p38MAPK
pathway showed no increase in cytoplasm, indicating the
inactivity of the p38MAPK pathway (Figure 3(a)).
We further determined whether the phosphorylated
ERK1/2, STAT6 and NF-κBp65 enter the nucleus to activate
DC-SIGN promoter directly or through other nuclear fac-
tors.Nuclearproteinswereextractedandthephosphorylated
kinase was tested by Western Blot. The results showed a
similar trend of increase of phosphorylated ERK1/2, STAT6,
and NF-κBp65 in the nucleus of PMA plus IL-4-induced
THP-1 cells within the ﬁrst 120min of IL-4 induction
(Figure 3(b)).
3.4. Ets-1 Transcription Factor Binding Site Makes the Main
Contribution to the Activity of DC-SIGN Promoter. Liu et al.
[29] reported that there are ﬁve nuclear transcription factor
binding sites (AP-1, SP-1, Ets-1, Lyf-1, and NF-κB) in the
cis acting elements of DC-SIGN promoter. We studied the
role of AP-1 and Ets-1 nuclear transcription factor binding
sites in the activity of DC-SIGN promoter, which are the
main nuclear factors exploited by ERK signaling pathway,
using luciferase reporter system. The sequence of complete
DC-SIGN promoter and the mutants with AP-1 or Ets-
1 binding site deletion were identiﬁed by gene sequencing
(Figure 4). The results showed that DC-SIGN promoterJournal of Biomedicine and Biotechnology 7
Position:    
Complete:      TCTGATGCTTTCCACTAGCCTTTTGGATGACAGATCCCTACCCAACTTCCTGTTTCTCTTTCTGTGGGAG  
AP-1 mutant: TCTGATGCTTTCCACTAGCCTTTTG CCCTACCCAACTTCCTGTTTCTCTTTCTGTGGGAG 
Ets-1 mutant: TCTGATGCTTTCCACTAGCCTTTTGGATGACAGATCCCTACCCA CTCTTTCTGTGGGAG 
+331 +400
Figure 4: Comparison of complete DC-SIGN promoter and the mutants with AP-1 or Ets-1 binding site deletion. The AP-1 binding site at
+356 to +365 and Ets-1 binding site at +375 to +385 of DC-SIGN promoter were deleted.
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Figure 5: The relative activity of complete DC-SIGN promoters and those without AP-1 or ETS-1 transcription factor binding factors.
The activities of luciferase reporter vectors of diﬀerent DC-SIGN promoters were detected in 293T cells (part a), Hacat cells (part b) and
untreated, PMA or PMA+IL-4-treated THP-1 cells (part c). The abbreviation in the ﬁgures: AP-B, pGL-3/Basic/DC-SIGN without AP-
1 transcription factor binding factor; AP-E, pGL-3/Enhancer/DC-SIGN without AP-1 transcription factor binding factor; ETS-B, pGL-
3/Basic/DC-SIGNwithoutETS-1transcriptionfactorbindingfactor;ETS-E,pGL-3/Enhancer/DC-SIGNwithoutETS-1transcriptionfactor
binding factor; B, pGL-3/Basic/DC-SIG; E, pGL-3/Enhancer/DC-SIGN; Negative, the internal control plasmid pRL-TK. ∗means P<0.05;
∗∗means P<0.01.
activity in THP-1 cells was much higher than in Hacat cells
and 293T cells. The deletion of Ets-1 nuclear transcription
factor binding site had signiﬁcant impact on the DC-SIGN
promoter activity, no matter in Hacat cells, 293T cells, and
untreated or PMA-treated or PMA plus IL-4-treated THP-1
cells. The activity of DC-SIGN promoters without Ets-1, no
matterthebasicorcontainingenhancers,almostdisappeared
completely (decreased more than 90%, P<0.05). The
activity of DC-SIGN promoters without AP-1 decreased
partially, from 28.60% to 47.88% in diﬀerent cell lines,
which was most obvious in the THP-1 cell line (P<0.05,
Figure 5).8 Journal of Biomedicine and Biotechnology
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Figure 6: Signaling pathways involved in IL-4-induced DC-SIGN expression on THP-1 cells. ERK signaling pathway plays a main role by
transcriptionfactorofEts-1toactiveDC-SIGNpromoter.JAK-STATandNF-κBsignalingpathwaysarealsoinvolved,whichmaybeinduced
by IL-4/IL-4R directly or by the interactions with ERK pathway indirectly.
4. Discussion
THP-1 cells can be diﬀerentiated into monocytes/macropha-
ges by PMA [30, 31]. Puig-Kr¨ oger et al. [32] found that
diﬀerentiated THP-1 cells can be induced into DCs by IL-
4 with the expression of DC-SIGN, and PMA stimulation
can greatly enhance DC-SIGN expression. Our study further
identiﬁed IL-4-diﬀerentiated THP-1 cells as a good in vitro
cell model of DC-SIGN expression. We found that IL-4 can
signiﬁcantly induce high expression of DC-SIGN in both
percentage of positive cells and expression density on the cell
surface, which demonstrates that DC-SIGN expression is IL-
4 dependent. The highest expression of DC-SIGN on THP-1
cells diﬀerentiated by PMA plus IL-4 was found at 72 hours
(24hforPMAand48hforPMAplusIL-4),whichwasdiﬀer-
ent from the results of Puig-Kr¨ oger’s study with the highest
e x p r e s s i o na t9 6h( 2 4hf o rP M Aa n d7 2hf o rP M Ap l u sI L -
4) [32]. And our study also found that the level of DC-SIGN
mRNAwassigniﬁcantlyincreased,indicatingthatexpression
of DC-SIGN is enhanced by IL-4 on the level of mRNA.
The IL-4-initiated signaling pathways that enhance
expression of DC-SIGN are still unclear. Researchers have
found that expression of many genes in T lymphocytes is
induced by IL-4 in an STAT-6-dependent manner [26, 27].
Recent studies have revealed that the JAK 2/3 inhibitor
tyrphostin AG-490 can prevent DC-SIGN upregulation on
MDDCs and diﬀerentiated THP-1 cells, suggesting that
STAT6 activation participates in IL-4-induced DC-SIGN
expression [14, 32]. IL-4-initiated STAT6 activation is not
suﬃcient for DC-SIGN upregulation to take place, because
IL-4 treatment of proliferating THP-1 cells leads to STAT6
activation, but not to DC-SIGN upregulation, thus suggest-
ing the involvement of additional pathways in the IL-4-
dependent DC-SIGN upregulation in THP-1 cells.Ourstudy
reveals that the ERK1/2 inhibitor PD98059 can almost com-
pletely inhibit the upregulated DC-SIGN expression induced
by IL-4, suggesting that IL-4-induced upregulation of DC-
SIGN expression is mainly dependent on the ERK MAPK
signaling pathway. And the JAK-STAT signaling pathway is
also involved in the process for the partial inhibition of IL-
4-induced DC-SIGN expression by STAT6 inhibitor AG490,
which is consistent with the previous studies [14, 32]. In
addition, in ERK MAPK signaling pathway, gene activation
is mainly regulated through the transcription factors Ets-
1 and AP-1, and the forming of a heterodimer of Ets-1
[33]. We further studied the activity of DC-SIGN promoters
without Ets-1 or AP-1 transcription factor binding sites
and found that the activity of DC-SIGN promoter without
Ets-1 transcription factor binding site almost completely
disappeared, indicating that the Ets-1 transcription factor
binding site plays a key role in the activation of DC-
SIGN promoter. The deletion of AP-1 transcription factor
binding site can make the activity of DC-SIGN promoter
decreased partly, the reason of which may be the block of
heterodimer of Ets-1 and AP-1 binding to the cis acting
elementsofDC-SIGNpromoter.Inaddition,wedetectedtheJournal of Biomedicine and Biotechnology 9
phosphorylation of protein kinase in the signaling pathways,
and found that the levels of phosphorylated ERK1/2 of ERK
pathway and phosphorylated STAT-6 of JAK-STAT pathway
gradually increased over time after IL-4 addition, which
provides direct evidence for the activation of the signaling
pathways. The increased levels of phosphorylated ERK1/2
and STAT-6 in the nucleus provide further proof of the
activation of the signaling pathways. No increased level of
phosphorylated p38 kinase is found in either the cytoplasm
or nucleus of diﬀerentiated THP-1 cells, indicating that the
p38 pathway, which also belongs to the family of MAPK
signaling pathways, like the ERK pathway, is not activated by
IL-4 in the expression of DC-SIGN.
Another signaling pathway we found involved in IL-4
induced high expression of DC-SIGN on THP-1 cells is the
NF-κB pathway, of relevance in a variety of inﬂammation
and immunological responses. Our previous study revealed
that the deletion of NF-κB transcription factor binding site
allows the activity of DC-SIGN promoter to be reduced by
half, and the overexpression of NF-κB protein can increase
the expression of DC-SIGN on THP-1 cells, suggesting
that NF-κB signaling pathway may be involved in the
expression of DC-SIGN [28]. Another study revealed that
dexamethasone, the inhibitor of NF-κB signaling pathway,
can reduce the expression of DC-SIGN [34]. Combined with
the reduced expression of DC-SIGN by inhibiting NF-κB
signaling pathway and the increase of phosphorylated NF-κB
in cytoplasm and nucleus of diﬀerentiated THP-1 cells, it can
be inferred that the NF-κB signaling pathway is also involved
in the process of upregulated DC-SIGN expression. The NF-
κB signaling pathway may be activated by two inducers. One
is PMA, which can induce the diﬀerentiation of THP-1 cells
throughactivationofPKCandNF-κBsignalingpathway.The
other is IL-4, which can directly activate the NF-κB signaling
pathway. The synergistic eﬀect of PMA and IL-4 found in
other studies, which can highly increase the expression of
DC-SIGN on THP-1 cells [14, 28, 32], can be attributed to
the activation of the NF-κB signaling pathway.
In summary, our study demonstrates that multiple sig-
naling pathways are involved in the process of IL-4-induced
high expression of DC-SIGN on THP-1 cells, in which ERK
pathway is the main signaling pathway, and JAK-STAT, and
NF-κB signaling pathways are also involved. The JAK-STAT
and NF-κB signaling pathways may be activated directly by
IL-4/IL-4 receptor, or by the ERK pathway indirectly. Com-
plex interactions may exist between the signaling pathways,
forming a regulatory network (see Figure 6). Further studies
are needed in the promotion or inhibition eﬀect between the
signaling pathways. In addition, the regulatory mechanisms
of intracellular signaling pathways vary in diﬀerent cells, and
signaling pathways regulating DC-SIGN expression should
be studied in other cells.
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